GlaxoSmithKline recently released long-term protection data for the herpes zoster vaccine. Research has shown that for people over 50 years old, the cumulative protection rate from the 6th to 11th year after receiving the Shingrix vaccine is as high as 79.7%, and the protection rate in the 11th year is still as high as 82%. For the population aged 70 and above, the cumulative protection rate from 6 to 11 years is as high as 73.1%. In 2023, the sales of GlaxoSmithKline Shingrix herpes zoster vaccine reached £ 3.446 billion (approximately RMB 31.422 billion), a year-on-year increase of 17%, making it the highest selling heavyweight product of GSK. (21st Century Business Herald)